文献速递皮肤肿瘤

黑色素瘤新靶点研发的兴起

The rise of new targets in melanoma.
PubMed 文献 · Br J Dermatol · 2025-01-01

本文综述了黑色素瘤治疗耐药问题及新靶点开发策略。NRAS突变目前无法用小分子药物靶向,BRAF V600突变患者接受BRAF/MEK联合治疗或免疫治疗后多数最终出现耐药。化学蛋白质组学平台和化学诱导邻近(CIP)制剂等新化学策略可快速扩展可成药靶点池,以NRAS、p53和SOX10为例说明如何克服耐药机制。

要点

  • NRAS是黑色素瘤第二常见突变驱动癌基因,目前仍无法用小分子药物靶向。
  • BRAF V600突变患者经BRAF/MEK联合治疗或免疫治疗后多数最终出现耐药。
  • 化学蛋白质组学和CIP制剂可快速扩展可成药靶点池以克服耐药。

核心结论

  • 利用化学蛋白质组学平台和化学诱导邻近(CIP)制剂等新化学策略,以NRAS、p53和SOX10等耐药介导蛋白为靶点,可快速扩展可成药靶点池并克服黑色素瘤耐药机制。

研究设计与样本

  • 本文为综述,检索范围未在原文中报告。

主要发现

  • NRAS是黑色素瘤中第二常见的突变驱动癌基因,目前仍无法用小分子药物靶向。
  • BRAF V600突变患者接受BRAF/MEK联合治疗或免疫治疗(不论体细胞遗传背景)后,多数最终出现耐药。
  • 化学蛋白质组学可快速鉴定配体以指导药物化学,CIP制剂可改变关键蛋白的表达水平。

临床怎么用

  • 可关注以NRAS、p53和SOX10等耐药介导蛋白为靶点的新化学策略在黑色素瘤治疗中的应用前景。

局限性

  • 本文为综述,未报告具体研究样本量、效应量或统计检验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite advancements in cancer treatment, the clinical options remain limited and therapeutic resistance inevitably develops. In melanoma, the second most commonly mutated driver oncogene is NRAS, which remains undruggable by small molecular agents. For those treated with BRAF/MEK combination therapy, in the setting of BRAF V600 mutations, or immunotherapies regardless of somatic genetic makeup, resistance eventually develops in the majority of cases. Developing rational combination therapies, as suggested by preclinical studies involving genetic manipulation of resistance mediators, necessitates a substantial expansion of druggable targets. Novel chemistry strategies, such as chemoproteomics platforms and chemical inducer of proximity (CIP) agents, offer promising solutions. Chemoproteomics enables the rapid identification of ligands to guide medicinal chemistry, while CIP agents alter the expression levels of key proteins. Using proteins encoded by oncogenes (such as NRAS) and p53 as pivotal resistance mediators, and the lineage-specific transcription factor SRY-box transcription factor 10 (SOX10) in melanoma as illustrative examples, we demonstrate how these technologies can be leveraged to rapidly expand the druggable target pool and overcome resistance mechanisms, ultimately paving the way for regimens that produce deeper and more durable responses. Even though cancer treatments have improved, people with cancer still have few treatment options. Many treatments stop working over time as cancer cells become resistant. Melanoma is the most dangerous type of skin cancer. It is often caused by mutations in a gene named NRAS. There are no drugs that can treat these NRAS mutations. For most patients who do not have NRAS mutations, resistance to treatment eventually develops after a certain period of time. To solve this problem, we need to understand how cancer cells become resistant. Recent studies suggest that targeting certain molecules that cause resistance might help. New methods are being studied. Chemoproteomics is a way to quickly find new drugs. ‘CIP agents’ are chemicals that can change the levels of important proteins involved in cancer and resistance. Researchers are focusing on proteins such as NRAS, p53 and SOX10 as potential new targets. Using these new technologies may help scientists find more drug targets for melanoma. Overall, this could lead to new cancer treatments that work better and last longer.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Bai X, Flaherty KT. The rise of new targets in melanoma. Br J Dermatol. 2025. PMID: 40570019. doi:10.1093/bjd/ljaf251

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。